Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma. (23rd April 2014)

• Record Type: Journal Article
• Authors: Wang, Erjian; Kang, Dongwoo; Bae, Kyun‐Seop; Marshall, Margaret A.; Pavlov, Dmitri; Parivar, Kourosh
• Is Part Of: Journal of clinical pharmacology. Volume 54:Number 10(2014:Oct.)
• Page Start: 1108
• Page End: 1116
• Publication Date: 2014-04-23
• Subjects: Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.309
• Languages: English
• ISSNs: 0091-2700

Abstract

<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="jcph309-sec-0001" sec-type="section"> <p>Tremelimumab, a fully human monoclonal antibody specific for human cytotoxic T‐lymphocyte‐associated antigen 4, has been studied in clinical trials. We have reported the results of population pharmacokinetics for tremelimumab in 654 metastatic melanoma patients. Population estimates (inter‐individual variability [IIV]) for pharmacokinetic parameters in a final model were clearance (CL), 0.26 L/day (31.8%) and central volume of distribution, 3.97 L (20.4%). CL was faster in males, patients with higher values of creatinine clearance and endogenous immunoglobulin, and patients with relatively poor baseline prognostic factors. No dose adjustment was needed based on the magnitude of the change of CL (<30%). The association of CL and overall survival (OS) was investigated. In a Phase 3 trial evaluating tremelimumab as first‐line‐treatment, median OS for the 147 patients in the fast‐CL group (≥median CL value) was 9.6 months versus 15.8 months for the 146 patients in the slow‐CL group (<median CL value). Multiple Cox proportional hazard regression models were constructed to evaluate the association between CL and OS adjusting for the effects of baseline prognostic covariates between two CL groups. The analysis showed statistically significant association between CL and OS (<italic>P</italic> < .05). Results suggest that higher or more frequent dosing should be considered in future trials.</p> </sec> </abstract>